Comprehensive treatment of intermediate and advanced primary hepatocellular carcinoma based on transcatheter arterial chemoembolization (Review)
- Authors:
- Xing Xu
- Xue Zhang
- Yang Zhao
- Xiaoyang Zhang
- Hongfang Tuo
-
Affiliations: Department of Hepatobiliary Surgery, Hebei General Hospital, Shijiazhuang, Hebei 050057, P.R. China, Department of Pathology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China - Published online on: May 7, 2025 https://doi.org/10.3892/ol.2025.15078
- Article Number: 332
This article is mentioned in:
Abstract
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N and Chen W: Cancer statistics in China and United States, 2022: Profiles, trends, and determinants. Chin Med J (Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Xu L, Zhang Y, Wang X, Shi M, Wang J, Tang Y, Fu Y, Zhou Z and Chen M: Transarterial infusion chemotherapy (TAI) combined with Sintilimab in locally advanced, potentially resectable hepatocellular carcinoma (HCC). Am Soc Clin Oncol. 38 (15 Suppl):e165932020. View Article : Google Scholar | |
|
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, et al: BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 76:681–693. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ahn JC, Qureshi TA, Singal AG, Li D and Yang JD: Deep learning in hepatocellular carcinoma: Current status and future perspectives. World J Hepatol. 13:2039–2051. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kloeckner R, Galle PR and Bruix J: Local and regional therapies for hepatocellular carcinoma. Hepatology. 73 (Suppl 1):S137–S149. 2021. View Article : Google Scholar | |
|
Holzner ML, Tabrizian P, Parvin-Nejad FP, Fei K, Gunasekaran G, Rocha C, Facciuto ME, Florman S and Schwartz ME: Resection of mixed hepatocellular-cholangiocarcinoma, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma. Liver Transpl. 26:888–898. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021. View Article : Google Scholar : PubMed/NCBI | |
|
Vogel A, Meyer T, Sapisochin G, Salem R and Saborowski A: Hepatocellular carcinoma. Lancet. 400:1345–1362. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K and Takashima S: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 148:397–401. 1983. View Article : Google Scholar : PubMed/NCBI | |
|
Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R and de Baere T: Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 72:28–36. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Department of Medical Administration, National Health Commission of the People's Republic of China, . Guideline for diagnosis and treatment of primary liver cancer (2024 edition). Chin J Dig Surg. 23:429–478. 2024.(In Chinese). | |
|
Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, et al: Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology. 73 (Suppl 1):S158–S191. 2021. View Article : Google Scholar | |
|
Okusaka T, Okada S, Ueno H, Ikeda M, Yoshimori M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Iwata R, et al: Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology. 58:293–299. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Yu TZ, Zhang W, Liu QX, Li WH, Ma JQ, Zhang ZH, Yang MJ, Wang JH, Chen B, Zeng SC, et al: Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus. Oncotarget. 8:12108–12119. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J, Guo JH, Ji JS, Li YL, Lv WF, Zhu HD, Sun JH, Ren WX, Zhang FJ, Wang WD, et al: Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: A multicenter randomized trial. Int J Surg. 109:1188–1198. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Hu B, Li W, Huang P, Zhang S, Zhong BY and Ni CF: 125I irradiation stent for hepatocellular carcinoma with main portal vein tumor thrombosis: A systematic review. Cardiovasc Intervent Radiol. 43:196–203. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Fan Z, Qian Z and Hao X: Combination use of TACE and 125I seed implantation for primary hepatic cancer complicated by portal vein tumor thrombus: A meta-analysis. J Interv Radiol. 28:268–275. 2019. | |
|
Chen L, Sun T, Kan X, Chen S, Ren Y, Cao Y, Yan L, Liang B, Xiong B and Zheng C: Transarterial chemoembolization combined with iodine-125 seed implantation for patients with hepatocellular carcinoma: A retrospective controlled study. J Int Med Res. 48:3000605209443092020. View Article : Google Scholar : PubMed/NCBI | |
|
Gao F, Gu YK, Huang JH, Zhang FJ and Wu PH: Clinical value of CT-guided (125)I brachytherapy for retroperitoneal metastatic lymph node from PHC. Zhonghua Yi Xue Za Zhi. 93:2155–2157. 2013.(In Chinese). PubMed/NCBI | |
|
Wang M, Ye X, Yuan G and He S: Advances in transcatheter arterial chemoembolization for primary liver cancer. Chin J Exp Surg. 37:1563–1568. 2020. | |
|
Li B, Gu TS, Zhang YB, Ai N, Liu H and Zhou ZG: Clinical effect of TACE and three-dimensional conformal radiotherapy in the treatment of advanced liver cancer. Chin Gen Pract. 20:4121–4124,4129. 2017. | |
|
Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, Lee HC and Lim YS: Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: A randomized clinical trial. JAMA Oncol. 4:661–669. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Guo W, Guo L, Lau WY, Ge N, Wang K and Cheng S: Should transarterial chemoembolization be given before or after intensity-modulated radiotherapy to treat patients with hepatocellular carcinoma with portal vein tumor thrombus? A propensity score matching study. Oncotarget. 9:24537–24547. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y, Zhu X, Wang H, Dong D, Gao S, Zhu X and Wang W: Safety and efficacy of transcatheter arterial chemoembolization plus radiotherapy combined with sorafenib in hepatocellular carcinoma showing macrovascular invasion. Front Oncol. 9:10652019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Q, Zhu K, Yue J, Qi Z, Jiang S, Xu X, Feng R and Wang R: Comparison of intra-arterial chemoembolization with and without radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis. Ther Clin Risk Manag. 13:21–31. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shui Y, Yu W, Ren X, Guo Y, Xu J, Ma T, Zhang B, Wu J, Li Q, Hu Q, et al: Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol. 13:1882018. View Article : Google Scholar : PubMed/NCBI | |
|
Wu FX, Lu HR, Zhu SL, Li ZH, Zou L, Bai T, Chen J, Yang TB and Liang SX: Efficacy of three-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. Onco Targets Ther. 9:7141–7147. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li N, Feng S, Xue J, Wei XB, Shi J, Guo WX, Lau WY, Wu MC, Cheng SQ and Meng Y: Hepatocellular carcinoma with main portal vein tumor thrombus: A comparative study comparing hepatectomy with or without neoadjuvant radiotherapy. HPB (Oxford). 18:549–556. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lewis AR, Padula CA, McKinney JM and Toskich BB: Ablation plus transarterial embolic therapy for hepatocellular carcinoma larger than 3 cm: Science, evidence, and future directions. Semin Intervent Radiol. 36:303–309. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Iezzi R, Pompili M, Posa A, Coppola G, Gasbarrini A and Bonomo L: Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art. World J Gastroenterol. 22:1935–1942. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang YJ, Chen MS, Chen Y, Lau WY and Peng Z: Long-term outcomes of transcatheter arterial chemoembolization combined with radiofrequency ablation as an initial treatment for early-stage hepatocellular carcinoma. JAMA Netw Open. 4:e21269922021. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan H, Liu F, Li X, Guan Y and Wang M: Transcatheter arterial chemoembolization combined with simultaneous DynaCT-guided radiofrequency ablation in the treatment of solitary large hepatocellular carcinoma. Radiol Med. 124:1–7. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu C, Li T, He JT and Shao H: TACE combined with microwave ablation therapy vs TACE alone for treatment of early- and intermediate-stage hepatocellular carcinomas larger than 5 cm: A meta-analysis. Diagn Interv Radiol. 26:575–583. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Yu H, Qi L, Liu C, Feng Y, Qi J, Li J and Zhu Q: Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: A systematic review and meta-analysis. Int J Hyperthermia. 39:455–465. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuang BW, Li W, Xie XH, Hu HT, Lu MD and Xie XY: Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis. Jpn J Clin Oncol. 49:845–855. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li B, Qiu J, Zheng Y, Shi Y, Zou R, He W, Yuan Y, Zhang Y, Wang C, Qiu Z, et al: Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma. Ann Surg Open. 2:e0572021. View Article : Google Scholar : PubMed/NCBI | |
|
Huang J, Huang W, Zhan M, Guo Y, Liang L, Cai M, Lin L, He M, Lian H, Lu L and Zhu K: Drug-eluting bead transarterial chemoembolization combined with FOLFOX-based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma. J Hepatocell Carcinoma. 8:1445–1458. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, Zhang X, Wang XD, Cao G, Chen H, et al: Combination therapy of chemoembolization and hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis compared with chemoembolization alone: A propensity score-matched analysis. Biomed Res Int. 2021:66703672021. View Article : Google Scholar : PubMed/NCBI | |
|
Dimri M and Satyanarayana A: Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. Cancers (Basel). 12:4912020. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, et al: Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 69:1492–1501. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Raoul JL, Decaens T, Burak K, Koskinas J, Villadsen GE, Heurgue-Berlot A, Bayh I, Cheng AL, Kudo M, Lee HC, et al: 710P-Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada. Ann Oncol. 29 (Suppl 8):viii2402018. View Article : Google Scholar | |
|
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Xiao W, Han Y, Cao S, Zhang Z, Chen G, Hu Y and Jin L: Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy. J Gastrointest Oncol. 13:1248–1254. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Hatanaka T, Naganuma A and Kakizaki S: Lenvatinib for hepatocellular carcinoma: A literature review. Pharmaceuticals (Basel). 14:362021. View Article : Google Scholar : PubMed/NCBI | |
|
Koyama N, Saito K, Nishioka Y, Yusa W, Yamamoto N, Yamada Y, Nokihara H, Koizumi F, Nishio K and Tamura T: Pharmacodynamic change in plasma angiogenic proteins: A dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. BMC Cancer. 14:5302014. View Article : Google Scholar : PubMed/NCBI | |
|
Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, Huang F, Tang R, Cheng Y, Huang Z, et al: Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 41:117–127. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Chen S, Wu Z, Shi F, Mai Q, Wang L, Wang F, Zhuang W, Chen X, Chen H, Xu B, et al: Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: A retrospective study. J Cancer Res Clin Oncol. 148:2115–2125. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo M: A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: Initial lenvatinib therapy with subsequent selective TACE. Liver Cancer. 8:299–311. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Tominaga L, Kajiwara A, Kasuya K, Iritani S, Fujiyama S, et al: Lenvatinib-transarterial chemoembolization sequential therapy as an effective treatment at progression during lenvatinib therapy for advanced hepatocellular carcinoma. Liver Cancer. 9:756–770. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao S, Zhang T, Dou W, Wang E, Wang M, Wang C, Du X and Liu L: A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: A systematic review and meta-analysis. Ann Transl Med. 8:5422020. View Article : Google Scholar : PubMed/NCBI | |
|
Liang B, Ma Y, Huang M, Zhang X, Yu L, Luo Y, Liu R, Zhou S, Xu G, Li HL, et al: 66O TACE combined with apatinib in patients with intermediate and advanced hepatocellular carcionma: A prospective, multi-center, randomized clinical trial. Ann Oncol. 33 (Suppl 9):S14552022. View Article : Google Scholar | |
|
Ueda S, Hori S, Hori A, Makitani K, Wan K and Sonomura T: Retrospective study of the efficacy and safety of chemoembolization with drug-eluting microspheres combined with intra-arterial infusion of bevacizumab for unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 9:973–985. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Fu R, Li Y, Jiang N, Ren BX, Zang CZ, Liu LJ, Lv WC, Li HM, Weiss S, Li ZY, et al: Inactivation of endothelial ZEB1 impedes tumor progression and sensitizes tumors to conventional therapies. J Clin Invest. 130:1252–1270. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Erinjeri JP, Fine GC, Adema GJ, Ahmed M, Chapiro J, den Brok M, Duran R, Hunt SJ, Johnson DT, Ricke J, et al: Immunotherapy and the interventional oncologist: Challenges and opportunities-A society of interventional oncology white paper. Radiology. 292:25–34. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tischfield DJ, Gurevich A, Johnson O, Gatmaytan I, Nadolski GJ, Soulen MC, Kaplan DE, Furth E, Hunt SJ and Gade TPF: Transarterial embolization modulates the immune response within target and nontarget hepatocellular carcinomas in a rat model. Radiology. 303:215–225. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
No authors listed. IMMUTACE: A phase 2 single-arm, open-label study of transarterial chemoembolization in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 17 (11 Suppl 6):S16–S17. 2021. | |
|
Marinelli B, Kim E, D'Alessio A, Cedillo M, Sinha I, Debnath N, Kudo M, Nishida N, Saeed A, Hildebrand H, et al: Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: Evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer. 10:e0042052022. View Article : Google Scholar : PubMed/NCBI | |
|
Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F and Wood BJ: Combined locoregional-immunotherapy for liver cancer. J Hepatol. 70:999–1007. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hao MZ, Lin HL, Chen Q, Ye YB, Chen QZ and Chen MS: Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: A comparative study. Chin J Cancer. 29:172–177. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
He G, Zheng C, Huo H and Zhang H, Zhu Z, Li J and Zhang H: TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: A meta-analysis. Int Immunopharmacol. 40:436–442. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX and Finn RS: Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 19:151–172. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW, Zhong BY, Sun JH, Jin ZC, Chen JJ, Ge NJ, et al: Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 8:582023. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q, Wu X, Song J, Zhao Z and Ji J: Efficacy and safety of TACE combined with sorafenib plus immune checkpoint inhibitors for the treatment of intermediate and advanced TACE-refractory hepatocellular carcinoma: A retrospective study. Front Mol Biosci. 7:6093222020. View Article : Google Scholar : PubMed/NCBI | |
|
Cai M, Huang W, Huang J, Shi W, Guo Y, Liang L, Zhou J, Lin L, Cao B, Chen Y, et al: Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: A retrospective cohort study. Front Immunol. 13:8483872022. View Article : Google Scholar : PubMed/NCBI | |
|
Tao W, Hung TC and Meng W: Efficacy of TACE combined with TKI and PD-1 inhibitors in conversion therapy for patients with unresectable hepatocellular carcinoma. Chin J Oncol Prev Treat. 13:413–419. 2021.(In Chinese). | |
|
Li X, Chen J, Wang X, Bai T, Lu S, Wei T, Tang Z, Huang C, Zhang B, Liu B, et al: Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors. Front Oncol. 13:11106892023. View Article : Google Scholar : PubMed/NCBI | |
|
Lingyi X, Fang F, Wah LK, Yin WW and Longmei L: Treatment of primary liver cancer by spleen-invigorating and qi-regulating method combined with TACE: A systematic review. World J Integr Tradit West Med. 14:1497–1504. 2019. | |
|
Bin L, Yao L, Ying F and Xianbo W: Effect of fuzheng jiedu xiaoji formula combined with transhepatic arterial chemoem-bolization on immune function and survival condition of primary hepatic carcinoma with qi-yin defi-ciency and toxin-stasis accumulation syndrome. J Tradit Chin Med. 63:1143–1148. 2022. | |
|
Ma Y, Wang C, Zhang Q, Peng X, Feng Y and Meng X: The effects of polysaccharides from Auricularia auricula (Huaier) in adjuvant anti-gastrointestinal cancer therapy: A systematic review and network meta-analysis. Pharmacol Res. 132:80–89. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jang JW, Choi JY, Bae SH, Kim CW, Yoon SK, Cho SH, Yang JM, Ahn BM, Lee CD, Lee YS, et al: Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol. 41:427–435. 2004. View Article : Google Scholar : PubMed/NCBI |
